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“watch” group antibiotics in India for
optimum use of antibiotics to contain
antimicrobial resistance
Sumanth Gandra1† and Anita Kotwani2*†
Antimicrobial resistance (AMR) is a growing public
health threat and one of its biggest drivers is in-
appropriate use of antibiotics [1]. To optimize the
use of antimicrobials, the World Health Organization
(WHO) in 2017 updated the Essential Medicine List
(EML) and categorized the antibiotics into three
groups- Access, Watch and Reserve (AWaRe) [2].
The Access group antibiotics are the first and second
choices for empirical treatment of 21 common clin-
ical syndromes. First choices are narrow spectrum
agents whereas second choice are broad spectrum
agents with higher resistance potential. Antibiotics
such as amoxicillin/ampicillin, benzathine penicillin,
trimethoprim-sulfamethoxazole, amoxicillin-clavulanic
acid, cloxacillin are first choice agents. Watch group
includes antibiotics with high resistance potential
when compared with the Access group and includes
antibiotics such as third generation cephalosporins,
fluoroquinolones and carbapenems. The Reserve
group includes antibiotics of last-resort like poly-
myxins, fourth and fifth generation cephalosporins.
WHO recommends that Access group of antibiotics
should be widely available and at an affordable cost and
minimize the use of other two groups of antibiotics. A re-
cent report analyzed antibiotic sales data in India between
2007 and 2012 which showed that the consumption of
Watch group and Reserve group antibiotics are increasing
rapidly when compared to Access group of antibiotics [3].
Here we discuss the consumption patterns of certain
antibiotics in Access group and Watch group and the rea-
sons for their consumption patterns.
Human antibiotic consumption in India is among the
highest in the world [4]. Antibiotic consumption in India
increased from 3.2 billion DDDs (defined daily doses) in
2000 to 6.5 billion DDDs in 2015 [4]. Although
per-capita consumption of antibiotics in India is low
when compared to several other countries [4], the pro-
portion of broad-spectrum antibiotics (Watch group and
Reserve group) consumption is high as evident in ana-
lysis of pediatric antibiotic sales data in 70 countries [5].
The use of third generation cephalosporins which be-
longs to Watch group is increasing rapidly in India [6].
In contrast to the rapid rise in the consumption of third
generation cephalosporins between 2000 and 2015, the
consumption of fluoroquinolones (Watch group antibi-
otics) is decreasing whereas penicillins (Access group
antibiotics) consumption remained constant [6].
The combination of broad-spectrum activity, availability
in oral and parenteral formulations, convenient dosing
and minimal adverse effects make second and third gener-
ation cephalosporins an ideal choice for prescribers in
both adults and children. Although, second and third gen-
eration cephalosporins offer several advantages, their use
increases the risk of colonization with extended spectrum
beta-lactamase (ESBLs) producing Enterobacteriaceae
(e.g.: E. coli) that are part of human normal intestinal flora
[7, 8]. The high prevalence of third generation cephalo-
sporin resistant Enterobacteriaceae among clinical isolates
obtained from both children and adults in India [9]
correlates well with the increasing consumption of third
generation cephalosporins due to selection pressure. In a
national scale study 2014, using a large private diagnostic
laboratory network data, approximately 80% of the E.coli
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isolates obtained from blood cultures were resistant to
third generation cephalosporins [9].
The increasing use of second and third generation ceph-
alosporins belonging to Watch group could be attributed
to combination of factors such as changing prescribing
practices, increasing antimicrobial resistance to other anti-
biotic classes and lack of availability of first-line penicillin
antibiotics belonging to Access group.
Changing prescribing practices
In a 2004 study assessing antibiotic consumption in
private retail pharmacies in Delhi showed that fluoroqui-
nolones were most commonly consumed antibiotics
followed by penicillins and cephalosporins [10].
Consumption of cephalosporins was about 39% less than
fluoroquinolone. A repeat study in 2007 in the same areas
in private retail pharmacies showed equal consumption of
cephalosporins and fluoroquinolones [11]. Three most
commonly prescribed cephalosporins were cefuroxime,
cefixime and combination of cefixime and clavulanic acid
all of which belonged to Watch group [11].Penicillins are
recommended as the first line antibiotics for treatment of
respiratory tract infections [12]. However, recent trends
indicate that penicillins are increasingly substituted by
second and third generation cephalosporins for treatment
of respiratory tract infections in both outpatient [13, 14]
and inpatient settings [15, 16]. In a study between Decem-
ber 2007 and November 2008 which conducted exit inter-
views of patients with upper respiratory tract infections
showed that in private clinics, cephalosporins were pre-
scribed to 39% of patients followed by fluoroquinolone
(24%), penicillins (19%) and macrolides (11%) [13]. How-
ever, in public clinics, the main class of antibiotics pre-
scribed were penicillins (31%), followed by macrolides
(25%), fluoroquinolones (20%) and cephalosporins
(10%). In a 2014 qualitative study involving focus-group
discussions and face-to-face interviews with doctors and
pharmacists to study the behavior and perception about
antibiotic use for acute upper respiratory tract infections
(URTIs) and diarrhea in children in New Delhi indicated
that some General Practitioners use cefixime and cefpo-
doxime for URTIs [14]. In a retrospective five-year study
between 2007 and 2012 among hospitalized patients with
community acquired pneumonia showed that cephalo-
sporin prescriptions significantly increased whereas peni-
cillin prescriptions significantly decreased over the study
period [15]. Among the total antibiotic prescriptions,
cephalosporin consumption increased from 16% in 2007
to 27% in 2012, whereas penicillins consumption
decreased from 30% in 2007 to 16% in 2012 [15]. In a re-
cent multicenter study involving six pediatric hospitals in
2016, third generation cephalosporins were the most
commonly prescribed antibiotics for lower respiratory
tract infections (LRTIs) and accounted for 37% of the pre-
scriptions for LRTIs among hospitalized children [16].
Changing prescribing practices among healthcare
providers could be due to multiple factors and one such
factor could be the influence of marketing and promo-
tion practices of drug manufactures. Although third
generation cephalosporins belonging to Watch group are
increasingly used for treatment of respiratory tract infec-
tions, studies indicate that penicillins belonging to
Access group are still active against the common bacter-
ial pathogens causing respiratory tract infections. In a
recent study examining resistance rates of pathogens
isolated from community acquired pneumonia patients
in India between 2012 and 2014, showed high suscepti-
bility to amoxicillin/ampicillin and amoxicillin-clavulanic
acid [17]. In this study, the susceptibility rates of Strepto-
coccus pneumoniae and Streptococcus pyogenes for
amoxicillin were 92 and 100%, respectively. For Hemo-
philus influenzae, ampicillin susceptibility was 91% and
amoxicillin/clavulanic acid was 97%, respectively [17].
These findings reassure prescribers to follow the
published treatment guidelines by National Center for
Disease Control and INDIACLEN Taskforce on Pneu-
monia, which recommend use of Access group of antibi-
otics (amoxicillin, amoxicillin-clavulanic acid and
ampicillin-gentamicin (in young children)) for commu-
nity acquired respiratory tract infections as empiric
treatment choice in both outpatient and inpatient set-
tings [18, 19]. Third generation cephalosporins belong-
ing to Watch group should be reserved for very sick
patients or patients admitted to intensive care units or
when there is a clinical deterioration on first line agents
belonging to Access group.
Increasing antimicrobial resistance to
fluoroquinolones
Quinolones belonging to Watch group have been the
main stay of treatment for enteric fever and bacterial
dysentery which account for a huge burden of infections
in India. Several recent studies reported increasing quin-
olone resistance among bacteria causing these infections.
In a national scale retrospective study on antimicrobial
susceptibility of various bacterial pathogens between
2008 and 2014, Salmonella Typhi resistance to nalidixic
acid was 98% [9]. Similarly, ciprofloxacin resistance
among S. Typhi was 69% in 2014 as per Indian Council
of Medical Research (ICMR) AMR surveillance network
hospitals [20]. Quinolone resistance among Shigella spp.
and Campylobacter spp. causing bacterial dysentery is
also increasing. In a recent study from South India
showed that Shigella flexneri and S. sonnei resistance to
nalidixic acid was greater than 95% [21]. Similarly, in a
study between 2008 and 2010 assessing the Campylobac-
ter spp. susceptibility patterns showed that 100% of the
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isolates were resistant to nalidixic acid and ciprofloxacin
[22]. Increasing quinolone resistance has resulted in the
use of third generation cephalosporins (ceftriaxone and
cefixime) belonging to Watch group as empiric treat-
ment choices for enteric fever and bacterial dysentery.
However, recent data indicate that S. Typhi has become
susceptible to older antibiotics like amoxicillin,
trimethoprim/sulfamethoxazole and chloramphenicol
which belong to Access group. In a national scale study
and 2014 ICMR AMR surveillance data, 95% of S. Typhi
isolates in 2014 were susceptible to ampicillin, chloram-
phenicol and trimethoprim/sulfamethoxazole [9, 20].
These results indicate the opportunity to examine and
report outcomes using older first-line antibiotics
(amoxicillin, trimethoprim/sulfamethoxazole and
chloramphenicol) belonging to Access group among
mild and moderately severe enteric fever cases especially
in centers where microbiological and antimicrobial
susceptibility services are available.
Lack of availability of narrow-spectrum antibiotics
The use of Watch group antibiotics namely second and
third generation cephalosporins is associated with
widespread availability of these antibiotics. A review of
the April–July 2017 edition of the Current Index of
Medical Specialties (CIMS) India, showed that 135
pharmaceutical companies were manufacturing cefixime
(third-generation cephalosporin), 103 were manufactur-
ing cefpodoxime (third generation cephalosporins) and
69 were manufacturing cefuroxime (second generation
cephalosporin) [6]. In contrast, 112 companies were
manufacturing amoxicillin-clavulanic acid, 51 were
manufacturing amoxicillin and only one company was
manufacturing penicillin and benzathine penicillin [6].
The lack of availability of Access group antibiotics such
as amoxicillin and benzathine penicillin was evident in
studies focused on availability of antibiotics in public
and private pharmacies. A study was conducted in New
Delhi (July–October 2011) to examine the access of anti-
biotics at primary care, secondary care and tertiary care
facilities of public health providers in Delhi and private
retail pharmacies [23]. The results indicated that ben-
zathine penicillin was not available at primary care, sec-
ondary care and tertiary care facilities of public sector
surveyed, whereas ampicillin suspension was available
only in 25% of primary care facilities and was not avail-
able in secondary and tertiary care facilities. However,
cefuroxime which is part of Delhi Government’s hospital
Essential Medicine List (EML)but not for primary care,
was available at 44% of primary care facilities. Cefixime
which was not part of Delhi Governments’ EML was
available in 22% of primary care facilities and 14% of
secondary care facilities. Similar to public sector,
benzathine penicillin was not available in any private
retail pharmacies however amoxicillin and cefixime were
available in greater than 90% of the private pharmacies
[23]. Interestingly, the median price ratio (MPR) of
second and third generation cephalosporins belonging to
Watch group is lower when compared to amoxicillin be-
longing to Access group in both public sector procure-
ment agencies and private retail pharmacies [23].The
MPR is the local median unit price of a medicine in
comparison with the median unit price of international
reference price which was found in the Management
Sciences for Health (MSH) Price Indicator Guide.
Conclusions
The current situation in India shows that there is excess
use and availability of Watch group of antibiotics com-
pared to Access group of antibiotics. Indian authorities
should consider revising the National EML and adopt
the WHO EML for antibiotics in three categories
(AWaRe) to optimize the use of antimicrobials. Mea-
sures should be taken by regulators and policy makers to
improve the availability and use of Access group of anti-
biotics and at the same time decrease the use of Watch
group of antibiotics that have higher resistance potential
in both public and private sector. A policy decision can
be taken to ask at least public sector pharmaceutical
manufacturing units to manufacture Access group of an-
tibiotics and these antibiotics should be available at gov-
ernment owned ‘Generic Drug’ stores and procured for
all public sectors. Standard treatment guidelines should
be prepared based on current sensitivity patterns and
implemented at public and private facilities so that doc-
tors start prescribing Access group of antibiotics as first
line drugs. Prescription audits at all level of healthcare
and feedback to prescribers and facility manager will fur-
ther improve the quality of prescribing.
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